Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

First nasal spray to treat Covid-19 in adults is here. Pharma company Glenmark has launched Nitric Oxide Nasal Spray, called FabiSpray in India, in partnership with SaNOtize.
The makers say that the spray will treat adult patients suffering from Covid-10, news agency ANI has reported.
Glenmark received manufacturing and marketing approval from India's drug regulator for Nitric Oxide Nasal Spray as part of the accelerated approval process.
The company said that phase 3 trial in India demonstrated reduction of viral load by 94 per cent in 24 hours and 99 per cent in 48 hours. "Nitric Oxide Nasal Spray was safe and well-tolerated in Covid-19 patients," an official statement said.
The company claims that when the Nitric Oxide Nasal is sprayed over nasal mucosa it acts as a physical and chemical barrier against the virus.
"FabiSpray is designed to kill the Covid-19 virus in the upper airways. When sprayed over nasal mucosa, it acts as a physical and chemical barrier against the virus, preventing it from incubating and spreading to the lungs," the statement said.
Terming the spray an effective and safe antiviral treatment for Covid-19, Glenmark Pharmaceuticals Ltd's Chief Commercial Officer Robert Crockart said "we are confident it will offer patients a much needed and timely therapy option."

First Nasal spray to treat Covid-19 launched in India. Check out details here

First Nasal spray to treat Covid&nbsp;patients launched in India
FabiSpray&nbsp;launched by Glenmark&nbsp;in partnership with SaNOtize
"Reduces viral load by 94% in 24 hours and 99% in 48 hours"
FabiSpray is designed to kill the COVID-19 virus in the upper airways
Company says the spray an effective and safe Covid treatment

Pharma company Glenmark has launched Nitric Oxide Nasal Spray, called FabiSpray in India, in partnership with SaNOtize.

First nasal spray to treat Covid-19 in adults is here. Pharma company Glenmark has launched Nitric Oxide Nasal Spray, called FabiSpray in India, in partnership with SaNOtize.
The makers say that the spray will treat adult patients suffering from Covid-10, news agency ANI has reported.
Glenmark received manufacturing and marketing approval from India's drug regulator for Nitric Oxide Nasal Spray as part of the accelerated approval process.
The company said that phase 3 trial in India demonstrated reduction of viral load by 94 per cent in 24 hours and 99 per cent in 48 hours. "Nitric Oxide Nasal Spray was safe and well-tolerated in Covid-19 patients," an official statement said.
The company claims that when the Nitric Oxide Nasal is sprayed over nasal mucosa it acts as a physical and chemical barrier against the virus.
"FabiSpray is designed to kill the Covid-19 virus in the upper airways. When sprayed over nasal mucosa, it acts as a physical and chemical barrier against the virus, preventing it from incubating and spreading to the lungs," the statement said.
Terming the spray an effective and safe antiviral treatment for Covid-19, Glenmark Pharmaceuticals Ltd's Chief Commercial Officer Robert Crockart said "we are confident it will offer patients a much needed and timely therapy option."

The Rs 1,500-crore-worth&nbsp;Glenmark&nbsp;Life IPO&nbsp;is oversubscribed by 50% on Day 1 as the investors look at the promising business ahead. From supplying&nbsp;API&nbsp;for a&nbsp;Covid&nbsp;drug to increasing manufacturing capacities, here's what is triggering the demand for the offering:
1. The company is expected to be supplying the API for Covid&nbsp;drug&nbsp;Favipiravir for Glenmark.
2. As on March 2021, the company has a portfolio of 120 molecules globally.&nbsp;16 of the 20 largest generic companies globally were its customers.
3. The future growth of its 120 molecules products is expected to remain stable driven by the increasing prevalence of non-communicable diseases like heart disease, stroke, cancer, diabetes and chronic lung disease.
4. The Company plans to increase its API manufacturing capabilities.
5.&nbsp;Expanding into Complex APIS such as oncology, iron replacement, peptides.

Glenmark Life IPO: Massive retail rush ovrsubscribed on Day 1, what's the buzz?

What's enthusing retail investors to Glenmark&nbsp;Life IPO. Here are 5 things you need to know to understand why the issue is getting oversubscribed.&nbsp;

Glenmark Life IPO subscribed 1.5x on Day 1; what is driving the interest

Glenmark&nbsp;Life is expected to be supplying the API for Covid&nbsp;drug&nbsp;Favipiravir for Glenmark

Retail investors are rushing towards the&nbsp;Rs 1,500-crore-worth&nbsp;Glenmark&nbsp;Life IPO&nbsp;which was full subscribed within hours of opening . So what is enthusing traders and investors in this pharma&nbsp;play Here is what you need to know about the Glemark Life-:
<ol>
<li>Growth Trigger: The company is expected to be supplying the API for Covid&nbsp;drug&nbsp;Favipiravir for Glenmark.</li>
<li>Promising Portfolio: With a strong showcase &nbsp;of 120 molecules globally.&nbsp;16 of the 20 largest generic companies globally were its customers.</li>
<li>Areas of Expertise: The future growth of its 120 molecules products is expected to remain stable driven by the increasing prevalence of non-communicable diseases like heart disease, stroke, cancer, diabetes and chronic lung disease.</li>
<li>Expansion: Plans to increase its API manufacturing capabilities.</li>
<li>Next Phase: Expanding into Complex APIs&nbsp;such as oncology, iron replacement, peptides.</li>
</ol>
Glenmark&nbsp;Life is also trading at a discount vs peers such as Divis&nbsp;Lab. The company will also be debt free post IPO&nbsp;and currently faces no regulatory issues on any of it's plants.&nbsp;

Glenmark&nbsp;Life Sciences'&nbsp;public issue or IPO&nbsp;will open on&nbsp;Tuesday&nbsp;and its scrips are already attracting a premium of over 20% in the grey markets. Here are all the details you need to know:
IPO&nbsp;issue date: July 27 to 29
Price band: Rs 695 to Rs 720 per equity share
Min quantity/lot size: 20 stocks
Lot price: Rs 13,900 (on lower price band)
IPO&nbsp;listing date: August 6, 2021
Grey market premium: Rs 150
Glenmark Life Sciences is a leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

Glenmark Life IPO opens today; Here is the grey market premium and issue details 

Glenmark&nbsp;Life Sciences'&nbsp;public IPO&nbsp;opens today, with a grey market premium already at 20% should you be investing?

Glenmark&nbsp;Life Sciences'&nbsp;public issue or IPO&nbsp;will open on&nbsp;Tuesday&nbsp;and its scrips are already attracting a premium of over 20% in the grey markets. Here are all the details you need to know:
IPO&nbsp;issue date: July 27 to 29
Price band: Rs 695 to Rs 720 per equity share
Min quantity/lot size: 20 stocks
Lot price: Rs 13,900 (on lower price band)
IPO&nbsp;listing date: August 6, 2021
Grey market premium: Rs 150
Glenmark Life Sciences is a leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

Glenmark Life Sciences is a leading manufacturer of Active Pharmaceutical Ingredients (APIs)

Glenmark&nbsp;Life Sciences'&nbsp;public issue or IPO&nbsp;opens on Tuesday and its scrips are already attracting a premium of over 20% in the grey markets. Here are all the details you need to know:
IPO&nbsp;issue date: July 27 to 29
Price band: Rs 695 to Rs 720 per equity share
Min quantity/lot size: 20 stocks
Lot price: Rs 13,900 (on lower price band)
Issue size: Rs 1,500 crore
IPO&nbsp;listing date: August 6, 2021
Grey market premium: Rs 150
Glenmark Life Sciences is a leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

Glenmark&nbsp;Life Sciences has filed its RHP&nbsp;and will be the fifth initial public offering (IPO) to open in July 2021. Here are some&nbsp;details:
Issue date: July 27 to 29
Issue size: Rs 1,600 crore
Listing date: August 6
Glenmark Life Sciences is a leading developer and manufacturer of select high-value&nbsp;Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management, and diabetes.&nbsp;The company develops, manufactures, and supplies high-quality&nbsp;APIs&nbsp;globally.

Glenmark Life Sciences files RHP; could raise Rs 1,600 cr via IPO

Glenmark&nbsp;Life Sciences has filed its RHP&nbsp;and will be the fifth initial public offering (IPO) to open in July 2021.

Glenmark Life manufactures APIs&nbsp;in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management, and diabetes.

Glenmark&nbsp;Life Sciences has filed its RHP&nbsp;and will be the fifth initial public offering (IPO) to open in July 2021. Here are some&nbsp;details:
Issue date: July 27 to 29
Price band: Rs 695 to Rs 720
Issue size: Rs 1,600 crore
Listing date: August 6
ALSO WATCH:&nbsp;<a href="Policybazaar%20IPO aims to raise Rs 6,500 crore likely to file DRHP in a week" target="_blank">Policybazaar IPO aims to raise Rs 6,500 crore likely to file DRHP in a week</a>
Glenmark Life Sciences is a leading developer and manufacturer of select high-value&nbsp;Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management, and diabetes.&nbsp;The company develops, manufactures, and supplies high-quality&nbsp;APIs&nbsp;globally.

IPO investors will be spoilt for choice this July as a flurry of IPOs&nbsp;will hit Dalal&nbsp;Street including much awaited names such as Zomato, Clean Science &amp; Glenmark.&nbsp;A total of 11 IPOs&nbsp;raising nearly Rs 24,000 cr will be available to investors to choose from.&nbsp;&nbsp;GR Infraprojects&nbsp;&amp; Clean Science would be the first to hit the street but investors are keenly awaiting the billion dollar issue from food tech giant Zomato&nbsp;later this month as well.&nbsp;This would be largest numbers of offerings in a single month since September 2010, and the amount of money to be raised in single month of July via IPOs&nbsp; tops the cumulative&nbsp;amount from January To June.&nbsp;Here is a list of the IPOs&nbsp;coming up that you can choose from-:

Zomato&nbsp;
Glenmark&nbsp;Life&nbsp;
Clean Science&nbsp;
Utkarsh&nbsp;SFB
Krsnaa&nbsp;Diagnostic&nbsp;
Shriram&nbsp;Properties&nbsp;
GR Infra&nbsp;
Rolex Rings
Windlas&nbsp;Biotech
Seven Island Shipping
Tatva&nbsp;Chintan&nbsp;Pharma&nbsp;

&nbsp;

IPO Downpour in July: 11 IPOs raising over Rs 24,000 cr which ones are you watching?

It's raining IPOs in July with nearly 3 IPOs&nbsp;scheduled every week, this month will see a total of 11 IPOs&nbsp;raising Rs 24,000 cr. Have you picked which IPO to invest in?

Raining IPOs in July, Have you picked which of the 11 IPOs to invest in?

20&nbsp;companies, including&nbsp;Zomato,&nbsp;Aditya Birla Sun Life AMC and Rolex Rings, have already filed papers with Sebi for a public offer and are expected to launch their IPOs in the second half of 2021 to raise more than Rs 40,000 crore.

IPO investors will be spoilt for choice this July as a <a href="https://www.edtr.ai/9gag">flurry of IPOs</a>&nbsp;will hit Dalal&nbsp;Street including much awaited names such as Zomato, Clean Science &amp; Glenmark&nbsp;Life. <a href="https://www.edtr.ai/9rsk" target="_blank">Read/Watch Also: Clean Science IPO&nbsp;commands 50% premium in grey market</a> A total of 11 IPOs&nbsp;raising nearly Rs 24,000 cr will be available to investors to choose from.&nbsp;&nbsp;GR Infraprojects&nbsp;&amp; Clean Science would be the first to hit the street but investors are keenly awaiting the billion dollar issue from food tech giant Zomato&nbsp;later this month as well.&nbsp; This would be largest numbers of offerings in a single month since September 2010, and the amount of money to be raised in single month of July via IPOs&nbsp; tops the cumulative&nbsp;amount raised from January To June.&nbsp; Here is a list of the IPOs&nbsp;coming up that you can choose from-:
<ul>
<li><a href="https://www.editorji.com/story/zomato-ipo-sebi-clears-the-way-to-deliver-1-billion-ipo-1625278933405">Zomato</a>&nbsp;</li>
<li>Glenmark&nbsp;Life&nbsp;</li>
<li>Clean Science&nbsp;</li>
<li>Utkarsh&nbsp;SFB</li>
<li>Krsnaa&nbsp;Diagnostic&nbsp;</li>
<li>Shriram&nbsp;Properties&nbsp;</li>
<li>GR Infra&nbsp;</li>
<li>Rolex Rings</li>
<li>Windlas&nbsp;Biotech</li>
<li>Seven Island Shipping</li>
<li>Tatva&nbsp;Chintan&nbsp;Pharma&nbsp;</li>
</ul>
&nbsp;

Here are the top 5 stocks on the traders' radar-:

Bandhan Bank: RBI&nbsp;nod coming for re-appointment of Chandra Shekhar Ghosh, Managing Director &amp; Chief Executive Officer of the bank, for a period of three years, with effect from July 10, 2021.
Glenmark Pharma: Unit gets IPO&nbsp;nod, Glenmark&nbsp;Life Sciences gets SEBI&nbsp;approval for IPO, parent company to sell 7.3 million shares via OFS&nbsp;
Prestige Estates: Net profit at Rs 1,336.3 crore against Rs 15.4 crore (YoY). One-time gain at Rs 1,469 crore.
Religare: To raise Rs 570 cr via preferential issue of shares, stock up 45% in one month&nbsp;
Max Financial: Brokerages bullish, CLSA&nbsp;maintains a Buy with a target of Rs 1350/share, a 30% upside from current prices


Max Financial, Religare, Prestige, Glenmark, Bandhan Bank: 5 stocks to watch

These are the top 5 stocks on the radar for traders and brokerages.&nbsp; #stockideas&nbsp;

Do you you have these 5 stocks on your radar ?

Here are the top 5 stocks on the traders' radar-:
<ol>
<li>Bandhan Bank: RBI&nbsp;nod coming for re-appointment of Chandra Shekhar Ghosh, Managing Director &amp; Chief Executive Officer of the bank, for a period of three years, with effect from July 10, 2021.</li>
<li>Glenmark Pharma: Unit gets IPO&nbsp;nod, Glenmark&nbsp;Life Sciences gets SEBI&nbsp;approval for IPO, parent company to sell 7.3 million shares via OFS&nbsp;</li>
<li>Prestige Estates: Net profit at Rs 1,336.3 crore against Rs 15.4 crore (YoY). One-time gain at Rs 1,469 crore.</li>
<li>Religare: To raise Rs 570 cr via preferential issue of shares, stock up 45% in one month&nbsp;</li>
<li>Max Financial: Brokerages bullish, CLSA&nbsp;maintains a Buy with a target of Rs 1350/share, a 30% upside from current prices</li>
</ol>

glenmark

Categories